Pepvio Research · Edition 1 · August 2026
We listened to 19,000 women.
Pepvio analyzed 19,075 public comments from women discussing menopause, weight, desire, energy, sleep, and focus. Nobody was surveyed, prompted, or paid. Nobody was identified. This is what women say when they are speaking freely about their experiences.
Finding one
Hot flashes are the stereotype. They ranked sixth.
Across 6,099 menopause comments, these are the symptoms women actually named, in order. The symptom on every brochure came last of the big six.
If your menopause does not look like the brochure, it is not just you. Mood, sleep, energy, weight, and clarity are the conversation. One commenter put it in capital letters: it is not just hot flashes.
Finding two
described a doctor dismissing them.
12.5%of study participants described a clinician dismissing, minimizing, or refusing to treat symptoms. The most common comment throughout the body of research: “I was told it was anxiety.”
The source of this finding, unprompted comments in response to menopause research queries, suggests that 12.5% is the minimum percentage of women who were dismissed in response to menopause concerns.
Finding three
For the symptoms women name most, the matching treatments are almost unknown.
Study participants described hormone therapy, supplements, and antidepressant medication as their options for sleep problems, fatigue, or brain fog. Less than a handful mentioned sermorelin, NAD+, or methylene blue, physician-prescribed therapies directly targeted at deeper sleep, cellular energy, and mental clarity. The reason is a lack of information about these options. Pepvio is here to close that information gap, so you know every option for treating your symptoms.
What they mentioned
- Hormone therapy470 mentions
- Supplements102 mentions
- Antidepressants42 mentions
Built for these symptoms, almost never mentioned
- Sermorelin3 mentions
- NAD+~0 mentions
- Methylene blue~0 mentions
6.4%
of comments in desire-related discussions were women and men asking where to get treatment safely and legitimately. The demand exists. A safe, physician-supervised path is what is missing from the conversation.
10.8%
of participants who commented on GLP-1 for weight loss were concerned about safety. People want to know that peptides are safe for them.
20.8%
of women reported having to see 2 or more doctors before getting help. Women should not have to shop MDs for their symptoms to be taken seriously.
This study is why Pepvio works the way it does
- ✓Women say menopause is: mood, sleep, energy, weight, and clarity, so our catalog treats it that way: HRT for the hormones, and physician-prescribed peptide protocols targeting sleep, cellular energy, and focus.
- ✓One in eight described being dismissed, so the visit starts from belief. You tell us why you're here. A licensed physician reviews what protocols are safe for you. You don't have to convince anyone that your symptoms are real.
- ✓You deserve transparency, so every price is published, every prescription comes from a licensed US physician, and every medication ships from a licensed US pharmacy.
Questions about the study
What are the most common menopause symptoms women actually talk about?
In Pepvio's analysis of 6,099 unprompted public comments from menopause discussions, the most-mentioned symptoms were mood changes and anxiety, followed by broken sleep, fatigue and low energy, weight and metabolism changes, and brain fog. Hot flashes, the symptom most associated with menopause, ranked sixth.
How common is it for doctors to dismiss menopause symptoms?
In this study, 12.5 percent of 6,099 menopause comments spontaneously described a clinician dismissing, minimizing, or refusing to treat the commenter's symptoms, without anyone asking about their medical care. Because these are unprompted mentions, the true rate of that experience is likely higher. A recurring phrase across the corpus was some version of "I was told it was anxiety."
What is the Pepvio Listening Study?
A recurring research program in which Pepvio analyzes large volumes of unprompted public comments from women discussing menopause, weight, desire, energy, sleep, and focus. Edition 1 covered 19,075 comments collected through official platform APIs and coded against a single published codebook, with hand-verified samples. No commenters are surveyed, prompted, paid, quoted, or identified.
Do women know about treatments for menopause fatigue, sleep, and brain fog?
Largely no. Among menopause commenters describing sleep problems, fatigue, or brain fog, the treatments mentioned were hormone therapy, supplements, and antidepressants. Therapies developed for exactly those symptoms, such as sermorelin for deep sleep or NAD+ for cellular energy, were mentioned almost never: three mentions of sermorelin and effectively zero for NAD+ and methylene blue across more than a thousand comments.
Methodology and limitations
Collection. 19,417 public comments were collected in August 2026 through the YouTube Data API (the platform's official interface) from comment sections under popular videos about menopause, hormone therapy, GLP-1 weight loss, desire, energy, sleep, and focus, found via 27 patient-experience search queries. Commenter identities were never stored. Raw text is retained only in a private research archive and is never published, quoted, or shared.
Coding. 19,075 comments were validly coded against a single fixed codebook covering symptoms, treatments mentioned, provider experiences, cost experiences, confusion types, and emotion, using Claude (Anthropic) as the coder. The dismissal code required an explicit first-person account of a clinician dismissing, minimizing, or refusing to treat the writer's own care; general complaints about medicine did not qualify.
Verification. Random samples of coded comments were reviewed by hand; the headline dismissal finding held an estimated 85 to 90 percent precision, and the finding replicated across two fully independent coding passes (12.9 percent and 12.5 percent) with the stricter definition applied in the second.
Limitations. Comment sections are not a population sample: they reflect people motivated to comment, under the videos they gathered around. Spontaneous-mention rates are floors, not prevalence estimates. Symptom and treatment counts are comment-level mentions. About 0.6 percent of the corpus was skipped as malformed. In desire-related discussions, peptide mentions predominantly refer to PT-141. Corrections and methodology questions: hello@pepvio.com.
Citing this study: “Pepvio Listening Study, Edition 1 · August 2026, pepvio.com/research/listening-study.” Journalists and researchers are welcome to the methodology detail behind any figure.